重组人血管内皮抑素对恶性胸腔积液的治疗效果

The clinical effects of recombinant human endostatin on malignant pleural effusion

目的比较胸腔注入不同剂量重组人血管内皮抑素对Ⅳ期肺腺癌伴胸腔积液的临床效果。方法回顾性分析2019年1月-2021年5月于我院就诊的Ⅳ期肺腺癌伴恶性胸腔积液患者140例,其中对照组、观察组分别70例,对照组:胸腔注入重组人血管内皮抑素45mg d1,d4,d7,4周一次;观察组:胸腔注入重组人血管内皮抑素90mg d1,d7,4周一次,连续3次为一疗程,最多2疗程。观察两组治疗患者临床症状缓解、生活质量及不良反应情况。结果观察组临床症状缓解率(51.43%)高于对照组(34.29%,P<0.05)。观察组日常生活改善能力(84.29%)高于对照组(74.29%,P<0.05)。两组不良反应轻微,为0~I级,毒副作用小。结论重组人血管内皮抑素90mg d1,7/4周胸腔注入可有效减少恶性胸腔积液生成、改善患者生活质量、提升临床疗效,且不良反应小,值得推广。

Objective To compare the clinical effects of intrapleural injection of different doses of recombinant human endostatin on stageⅣlung adenocarcinoma with pleural effusion.Methods 140 patients with stageⅣlung adenocarcinoma with malignant pleural effusion who were treated in our hospital from January 2019 to May 2021 were retrospectively analyzed,including 70 cases in the control group and 70 cases in the observation group,respectively.In the control group:intrathoracic injection of recombinant human endostatin 45mg on d1,d4,d7,once every 4 weeks;In the observation group:intrathoracic injection of recombinant human endostatin 90 mg on d1,d7,and once every 4 weeks,three consecutive times as a course of treatment,up to two courses.The remission of clinical symptoms,quality of life,and adverse reactions of the two groups were observed.Results The remission rate of clinical symptoms in the observation group was(51.43%),which was higher than(34.29%)in the control group,P<0.05.The daily improvement ability of the observation group was(84.29%),which was higher than(74.29%)in the control group,P<0.05.The adverse reactions of the two groups were mild,grade 0~I,and the toxic and side effects were small.Conclusion Recombinant human endostatin 90 mg on d1,d7,per 4 weeks intrapleural injection can effectively reduce the generation of malignant pleural effusion,improve the quality of life of patients,improve the clinical efficacy,and has fewer adverse reactions,which is worthy of promotion.